H1 confirms the case, FCF set to grow strongly; chg.

LIMES H1'25: sales +29% to € 29.7m, EBITDA € 7.0m (23.6% margin); new clinics already EBITDA-positive; FCF inflects to € 4.8m. Boccella on track. BUY, € 810 PT.